TrademarkIQ íconeTrademarkIQ
Voltar para busca
Dado oficial do USPTO

ASCENDIS PHARMA

Sabia que essa marca já está registrada no Estados Unidos?

Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.

Active USPTO registrationTipo: MistaEscritório: US

Snapshot rápido

ASCENDIS PHARMA

ST13

US500000079225147

Classe

5, 42, 45

Pedido

79225147

Registro

6630735

Diagnóstico de risco e oportunidade

Leitura executiva para decisão de naming, protocolo e monitoramento.

Atenção: há risco ativo

Situação USPTO

Active USPTO registration

Tipo de processo

Pedido e registro

Eventos registrados

72

Atualização mais recente

13/03/2026

Classificação

Registrada

Tipo de marca

Mista

Classes Nice

5, 42, 45

Data de depósito

11/10/2017

Data de registro

01/02/2022

Data de expiração

-

Ação recomendada

Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.

Próximo passo

Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.

Dados completos do processo

Campos estruturados da autoridade responsável e do histórico oficial.

Data da situação

01/02/2022

Última transação

13/03/2026

Escritório responsável

United States Patent and Trademark Office

Código da situação

700

Cadastro oficial

Principal Register

Código do desenho

3

Tipo de titular

98

Localização do titular

DK

Examinador

SHOOR, AMIT KUMAR

Unidade examinadora

M80

Localização atual

PUBLICATION AND ISSUE SECTION

Descrição da marca

The mark consists of the turquoise word "ASCENDIS" under which is the grey word "PHARMA" next to a polygon broken by a white curved band in which the top is turquoise and the bottom is blue.

Titulares e representantes

Titulares

Ascendis Pharma A/S
Ascendis Pharma A/S

Representantes

Eric T. Fingerhut Dykema Gossett PLLC

Classificação técnica

Classes Nice

Classe 5Classe 42Classe 45

Códigos Vienna

Sem códigos Vienna disponíveis.

Produtos e serviços

Classe 5

Pharmaceutical and veterinary preparations for the treatment of physical and mental illness, namely, pharmaceutical preparations for use in enzyme replacement therapy; pharmaceutical and veterinary preparations, namely, vaccines for the treatment of physical and mental illness; pharmaceutical and veterinary preparations for the treatment of physical and mental illness, namely, pharmaceutical preparations for the prevention and treatment of disorders of the endocrine system, growth hormone deficiencies, hypoparathyroidism, achondroplasia, diabetes, fibroblast growth factor receptor(FGFR)-related skeletal disorders, oncological disorders, ophthalmologic disorders, infectious diseases, enzyme replacement therapy, anti-inflammatory diseases, pain, respiratory system disorders, autoimmune disorders, vaccines, non-alcoholic steatohepatitis, brain diseases, bone diseases, CNS diseases, myopathies, obesity, wounds healing, the hormonal system disorders, namely, growth hormone deficiencies, diabetes and angiogenesis, the ophthalmological system disorders, namely, angiogenesis, the angiogenic system disorders, the central nervous system disorders, namely, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, the immune system disorders, namely, immunologic diseases, namely, autoimmune diseases and immunologic deficiency syndromes, the cardio-vascular system diseases, the metabolic system disorders, namely, diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia, the respiratory system, the musculo-skeletal system disorders, namely, growth hormone deficiencies, connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains, cartilage injuries, the genitourinary system disorders, namely, urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases; pharmaceutical preparations for the treatment of inflammatory disorders, namely, anti-inflammatories; pharmaceutical preparations for use in dermatology, namely, dermatitis, eczema, psoriasis; pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in hematology; pharmaceutical preparations for use in tissue and organ transplantation; pharmaceutical preparations for use in in ophthalmology pharmaceutical preparations for use in the treatment of gastroenterological disorders; sanitary preparations for medical purposes, namely, sanitizing wipes, disinfectants for medical instruments, adhesive tapes for medical purposes, dietetic foods, namely, dietetic sugar substitutes adapted for medical use, all-purpose disinfectants for sanitary purposes; fungicides, herbicides

Classe 42

Scientific research within the medical, pharmaceutical and bacteriological area and providing scientific consultancy and information in relation to the aforementioned scientific research, conducting of tests regarding medical applications, namely, conducting clinical trials for others, packaging design, designing and development of medical equipment, designing pharmaceutical and medical preparations, preparation of pharmaceutical formulations, namely, pharmaceutical products development, design and development of granulation technology and tablet technology and providing scientific consultancy and information relating to the design and development of granulation technology and tablet technology

Classe 45

Licensing of industrial property; legal services

Publicações

Histórico de despachos e eventos da marca no USPTO.

72 publicações encontradas

ADCH

CHANGE OF NAME/ADDRESS REC'D FROM IB

12/03/2026

NREP

NEW REPRESENTATIVE AT IB RECEIVED

10/03/2024

FINO

FINAL DECISION TRANSACTION PROCESSED BY IB

01/08/2022

FICS

FINAL DISPOSITION NOTICE SENT TO IB

13/07/2022

FIMP

FINAL DISPOSITION PROCESSED

13/07/2022

FICR

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

01/05/2022

R.PR

REGISTERED-PRINCIPAL REGISTER

01/02/2022

NREP

NEW REPRESENTATIVE AT IB RECEIVED

24/12/2021

GPNX

NOTIFICATION PROCESSED BY IB

23/11/2021

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

16/11/2021

PUBO

PUBLISHED FOR OPPOSITION

16/11/2021

NREP

NEW REPRESENTATIVE AT IB RECEIVED

28/10/2021

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

27/10/2021

OP2R

NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB

27/10/2021

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

27/10/2021

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

13/10/2021

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

12/10/2021

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

12/10/2021

ERFR

TEAS REQUEST FOR RECONSIDERATION RECEIVED

12/10/2021

GNFN

NOTIFICATION OF FINAL REFUSAL EMAILED

09/07/2021

GNFR

FINAL REFUSAL E-MAILED

09/07/2021

CNFR

FINAL REFUSAL WRITTEN

09/07/2021

DOCK

ASSIGNED TO EXAMINER

10/06/2021

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

16/03/2021

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

15/03/2021

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

15/03/2021

CHAN

APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED

15/03/2021

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

15/03/2021

ECDR

TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS

15/03/2021

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

15/03/2021

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

15/03/2021

COAR

TEAS CHANGE OF OWNER ADDRESS RECEIVED

15/03/2021

EWOR

TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED

15/03/2021

EWAF

TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS

15/03/2021

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

14/09/2020

GNRT

NON-FINAL ACTION E-MAILED

14/09/2020

CNRT

NON-FINAL ACTION WRITTEN

14/09/2020

RCCK

SUSPENSION CHECKED - TO ATTORNEY FOR ACTION

18/06/2020

ALIE

ASSIGNED TO LIE

03/06/2020

RCSC

REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED

21/11/2019

OPNX

NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB

05/07/2019

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

19/06/2019

OPNR

NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB

19/06/2019

RCSC

REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED

09/05/2019

GNS3

NOTIFICATION OF LETTER OF SUSPENSION E-MAILED

19/10/2018

GNSL

LETTER OF SUSPENSION E-MAILED

19/10/2018

CNSL

SUSPENSION LETTER WRITTEN

19/10/2018

DMCC

DATA MODIFICATION COMPLETED

01/10/2018

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

28/09/2018

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

27/09/2018

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

27/09/2018

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

14/09/2018

GNRT

NON-FINAL ACTION E-MAILED

14/09/2018

CNRT

NON-FINAL ACTION WRITTEN

14/09/2018

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

17/08/2018

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

17/08/2018

ALIE

ASSIGNED TO LIE

16/08/2018

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

26/07/2018

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

24/07/2018

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

24/07/2018

RFNT

REFUSAL PROCESSED BY IB

02/03/2018

RFCS

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

09/02/2018

RFRR

REFUSAL PROCESSED BY MPU

09/02/2018

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

07/02/2018

CNRT

NON-FINAL ACTION WRITTEN

06/02/2018

RFWR

NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW

02/02/2018

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

30/01/2018

CNRT

NON-FINAL ACTION WRITTEN

29/01/2018

MAFR

APPLICATION FILING RECEIPT MAILED

23/01/2018

DOCK

ASSIGNED TO EXAMINER

19/01/2018

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

19/01/2018

REPR

SN ASSIGNED FOR SECT 66A APPL FROM IB

18/01/2018

Proteção contínua da sua marca

Seja avisado a cada novo depósito que ameace ASCENDIS PHARMA ou a sua marca.

Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.